Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas.

ABSTRACT:

Background

Programmed death-ligand 1 (PD-L1) expression is the only FDA-approved biomarker for immune checkpoint inhibitors (ICIs) in patients with lung adenocarcinoma, but sensitivity is modest. Understanding the impact of molecular phenotype, clinical characteristics, and tumor features on PD-L1 expression is largely unknown and may improve prediction of response to ICI.

Patients and methods

We evaluated patients with lung adenocarcinoma for whom PD-L1 testing and targeted next-generation sequencing (using MSK-IMPACT) was performed on the same tissue sample. Clinical and molecular features were compared across PD-L1 subgroups to examine how molecular phenotype associated with tumor PD-L1 expression. In patients treated with anti-PD-(L)1 blockade, we assessed how these inte

SUBMITTER: Schoenfeld AJ 

PROVIDER: S-EPMC7523592 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature